Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Associated With Partial Melanoma Response Under Anti-Ctla-4 and Anti-Pd-1 Combination

Arthritis and Rheumatology - United Kingdom
doi 10.1002/art.40506
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

RS3PE (Remitting Seronegative Symmetrical Synovitis With Pitting Edema)-Syndrom

Forum Médical Suisse ‒ Swiss Medical Forum
2003English

Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Syndrome Accompanied by Parkinson's Disease

Internal Medicine
Internal MedicineMedicine
2007English

A Patient With Suspected Remitting Seronegative Symmetrical Synovitis With Pitting Edema(RS3PE) Syndrome Who Underwent Hemodialysis

Nihon Toseki Igakkai Zasshi
2011English

Remitting Seronegative Symmetrical Synovitis With Pitting Oedema (RS3PE) Syndrome: A Prospective Follow Up and Magnetic Resonance Imaging Study

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1999English

Paraneoplastic Remitting Seronegative Symmetrical Synovitis With Pitting Edema Syndrome Should Be Treated With Low-Dose Prednisolone During Pembrolizumab Therapy

Internal Medicine
Internal MedicineMedicine
2020English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Paraneoplastic Remitting Seronegative Symmetrical Synovitis With Pitting Edema Syndrome Should Be Treated With Low-Dose Prednisolone During Pembrolizumab Therapy: The Author's Reply

Internal Medicine
Internal MedicineMedicine
2020English

Intestinal Microbiota Predict Response and Toxicities During Anti-Pd-1/Anti-Ctla-4 Immunotherapy

Pathology
Forensic MedicinePathology
2020English

Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’

British Journal of Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy